Aduhelm Approval Boosts Other Alzheimer’s Drug Developers
Even Companies Not Focused On Clearing Amyloid Benefitted
Executive Summary
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
You may also be interested in...
IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
Amylyx Will Submit ALS Drug For Approval In The Coming Months
After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.
Muna Launches On 'Rising Tide' Of Alzheimer's
Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.